Jean Jacques Bienaime Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jean Jacques Bienaime is Director of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 473,792 shares of BMRN, which is worth approximately $30.3 Million. The most recent transaction as insider was on Feb 18, 2021, when has been sold 7,000 shares (Common Stock) at a price of $26.49 per share, resulting in proceeds of $185,430. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K

0% 3M change

12.91% 12M change

Total Value Held $30.3 Million

JEAN JACQUES BIENAIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2021	BUY Exercise of conversion of derivative security	$185,430 $26.49 p/Share	7,000 Added 2.26%	302,552 Common Stock
Feb 17 2021	SELL Open market or private sale	$676,320 $84.54 p/Share	8,000 Reduced 2.64%	295,552 Common Stock
Feb 17 2021	BUY Exercise of conversion of derivative security	$211,920 $26.49 p/Share	8,000 Added 2.57%	303,552 Common Stock
Jan 29 2021	SELL Open market or private sale	$688,972 $82.67 p/Share	8,334 Reduced 2.74%	295,552 Common Stock
Jan 29 2021	BUY Exercise of conversion of derivative security	$220,768 $26.49 p/Share	8,334 Added 2.67%	303,886 Common Stock
Jan 28 2021	SELL Open market or private sale	$690,889 $82.91 p/Share	8,333 Reduced 2.74%	295,552 Common Stock
Jan 28 2021	BUY Exercise of conversion of derivative security	$220,741 $26.49 p/Share	8,333 Added 2.67%	303,885 Common Stock
Jan 27 2021	SELL Open market or private sale	$712,388 $85.49 p/Share	8,333 Reduced 2.74%	295,552 Common Stock
Jan 27 2021	BUY Exercise of conversion of derivative security	$220,741 $26.49 p/Share	8,333 Added 2.67%	303,885 Common Stock
Dec 29 2020	SELL Open market or private sale	$132,270 $88.18 p/Share	1,500 Reduced 0.5%	295,552 Common Stock
Dec 28 2020	SELL Open market or private sale	$133,155 $88.77 p/Share	1,500 Reduced 0.5%	297,052 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

KROS

Keros Therapeutics, Inc. Healthcare

IMNM

Immunome Inc. Healthcare

JJB